Open Access Open Access  Restricted Access Subscription Access

An Essential Parameters of Captopril Include Objectives, Mechanism of Action, Pharmaco Kinetics, Administration, Adverse Effects, Drug-Drug Interaction, Contra Indications, Toxicity and Health Care Team Outcomes

Srinivas G., Ramanjaneyulu D. V., Satyanarayana Murthy S., Muralinath E., Guruprasad M., Hari Kiran M., Shaik Mahabooob Basha, Kundara Giridhar Reddy, Kasireddy Gauthami, Mopoori Kalyan, Sai Charan B., Sainath Reddy T., Ramesh U., Rahul P., Rajitha V.

Abstract


Captopril is an FDA-approved medication that plays an important regarding management of hypertension, left ventricular dysfunction post-myocardial infarction, and diabetic nephropathy. It is a key component in the therapy of these cardiovascular disorders since it mainly works by blocking the renin-angiotensin-aldosterone system (RAAS). By preventing the conversion of angiotensin I to angiotensin II, captopril effectively reduces the pathophysiological cascades that lead to hypertension and heart failure. This activity explains regarding captopril's mechanism of action, dosage considerations, pharmacodynamics, and monitoring strategies. Besides. captopril's off-label uses in acute hypertensive crises, and the Raynaud phenomenon will be discussed, equipping clinicians and inter professional team members along with essential knowledge to administer captopril. Understanding its adverse event profile and potential toxicities is essential for the safe and effective incorporation of captopril into clinical practice.


Full Text:

PDF

References


Chen, Y. J., Li, L. J., Tang, W. L., Song, J. Y., Qiu, R., Li, Q., Xue, H., & Wright, J. M. (2018). First-line drugs inhibiting the renin-angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews, 2018(11), CD008170.

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., ... Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), e263–e421.

Rout, P., & Jialal, I. (2025, January 9). Diabetic nephropathy. In StatPearls [Internet]. StatPearls Publishing.

de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022). Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care, 45(12), 3075–3090.

Karakiliç, E., Büyükcam, F., Kocalar, G., Gedik, S., & Atalar, E. (2012). Same effect of sublingual and oral captopril in hypertensive crisis. European Review for Medical and Pharmacological Sciences, 16(12), 1642–1645.

Damasceno, A., Ferreira, B., Patel, S., Sevene, E., & Polónia, J. (1997). Efficacy of captopril and nifedipine in Black and White patients with hypertensive crisis. Journal of Human Hypertension, 11(8), 471–476.

Musa, R., & Qurie, A. (2023, August 8). Raynaud disease. In StatPearls [Internet]. StatPearls Publishing.

Tosi, S., Marchesoni, A., Messina, K., Bellintani, C., Sironi, G., & Faravelli, C. (1987). Treatment of Raynaud's phenomenon with captopril. Drugs under Experimental and Clinical Research, 13(1), 37–42.

Gan, Z., Huang, D., Jiang, J., Li, Y., Li, H., & Ke, Y. (2018). Captopril alleviates hypertension-induced renal damage, inflammation, and NF-κB activation. Brazilian Journal of Medical and Biological Research, 51(11), e7338.

Lezama-Martinez, D., Flores-Monroy, J., Fonseca-Coronado, S., Hernandez-Campos, M. E., Valencia-Hernandez, I., & Martinez-Aguilar, L. (2018). Combined antihypertensive therapies that increase expression of cardioprotective biomarkers associated with the renin-angiotensin and kallikrein-kinin systems. Journal of Cardiovascular Pharmacology, 72(6), 291–295.

Herman, L. L., Padala, S. A., Ahmed, I., & Bashir, K. (2023, July 31). Angiotensin-converting enzyme inhibitors (ACEI). In StatPearls [Internet]. StatPearls Publishing.

Ho, J. K., Moriarty, F., Manly, J. J., Larson, E. B., Evans, D. A., Rajan, K. B., Hudak, E. M., Hassan, L., Liu, E., Sato, N., Hasebe, N., Laurin, D., Carmichael, P. H., & Nation, D. A. (2021). Blood-brain barrier crossing renin-angiotensin drugs and cognition in the elderly: A meta-analysis. Hypertension, 78(3), 629–643.

Zisaki, A., Miskovic, L., & Hatzimanikatis, V. (2015). Antihypertensive drugs metabolism: An update to pharmacokinetic profils and computational approaches. Current Pharmaceutical Design, 21(6), 806–822.

Duchin, K. L., McKinstry, D. N., Cohen, A. I., & Migdalof, B. H. (1988). Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clinical Pharmacokinetics, 14(4), 241–259.

Prescrire Editorial Team. (2014). Treating essential hypertension: The first choice is usually a thiazide diuretic. Prescrire International, 23(152), 215–220.

Ogawa, R., Stachnik, J. M., & Echizen, H. (2014). Clinical pharmacokinetics of drugs in patients with heart failure: An update (Part 2, drugs administered orally). Clinical Pharmacokinetics, 53(12), 1083–1114.

De Leo, F., Panarese, S., Gallerani, R., & Ceci, L. R. (2009). Angiotensin converting enzyme (ACE) inhibitory peptides: Production and implementation of functional food. Current Pharmaceutical Design, 15(31), 3622–3643.

Adeghate, E., Kalasz, H., Veress, G., & Teke, K. (2010). Medicinal chemistry of drugs used in diabetic cardiomyopathy. Current Medicinal Chemistry, 17(6), 517–551.

Biggins, S. W., Angeli, P., Garcia-Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021). Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 74(2), 1014–1048.

Lindle, K. A., Dinh, K., Moffett, B. S., Kyle, W. B., Montgomery, N. M., Denfield, S. D., & Knudson, J. D. (2014). Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. Pediatric Cardiology, 35(3), 499–506.

Regitz-Zagrosek, V., Roos-Hesselink, J. W., Bauersachs, J., Blomström-Lundqvist, C., Cífková, R., De Bonis, M., Iung, B., Johnson, M. R., Kintscher, U., Kranke, P., Lang, I. M., Morais, J., Pieper, P. G., Presbitero, P., Price, S., Rosano, G. M. C., Seeland, U., Simoncini, T., Swan, L., & Warnes, C. A. (2018). 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 39(34), 3165–3241.

Flynn, J. T., Kaelber, D. C., Baker-Smith, C. M., Blowey, D., Carroll, A. E., Daniels, S. R., de Ferranti, S. D., Dionne, J. M., Falkner, B., Flinn, S. K., Gidding, S. S., Goodwin, C., Leu, M. G., Powers, M. E., Rea, C., Samuels, J., Simasek, M., Thaker, V. V., Urbina, E. M., & Subcommittee on Screening and Management of High Blood Pressure in Children. (2017). Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics, 140(3), e20171904.

Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., Wainford, R. D., Williams, B., & Schutte, A. E. (2020). 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension, 75(6), 1334–1357.

Prieto-García, L., Pericacho, M., Sancho-Martínez, S. M., Sánchez, Á., Martínez-Salgado, C., López-Novoa, J. M., & López-Hernández, F. J. (2016). Mechanisms of triple whammy acute kidney injury. Pharmacology & Therapeutics, 167, 132–145.

Sánchez-Borges, M., & González-Aveledo, L. A. (2010). Angiotensin-converting enzyme inhibitors and angioedema. Allergy, Asthma & Immunology Research, 2(3), 195–198.


Refbacks

  • There are currently no refbacks.